Journal
STEM CELL REPORTS
Volume 14, Issue 5, Pages 909-923Publisher
CELL PRESS
DOI: 10.1016/j.stemcr.2020.03.012
Keywords
-
Categories
Funding
- Ministry of Health, Labour and Welfare of Japan
- Japan Agency for Medical Research and Development (A-MED)
- Japan Society for the Promotion of Science KAKENHI [16K19654]
- Grants-in-Aid for Scientific Research [16K19654] Funding Source: KAKEN
Ask authors/readers for more resources
GM1 gangliosidosis is a lysosomal storage disease caused by loss of lysosomal beta-galactosidase activity and characterized by progressive neurodegeneration due to massive accumulation of GM1 ganglioside in the brain. Here, we generated induced pluripotent stem cells (iPSCs) derived from patients with GM1 gangliosidosis, and the resultant neurons showed impaired neurotransmitter release as a presynaptic function and accumulation of GM1 ganglioside. Treatment of normal neurons with GM1 ganglioside also disturbed presynaptic function. A high-content drug-screening system was then established and identified two compounds as drug candidates for GM1 gangliosidosis. Treatment of the patient-derived neurons with the candidate agents activated autophagy pathways, reducing GM1 ganglioside accumulation in vitro and in vivo, and restoring the presynaptic dysfunction. Our findings thus demonstrated the potential value of patient-derived iPSC lines as cellular models of GM1 gangliosidosis and revealed two potential therapeutic agents for future clinical application.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available